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ABSTRACT: Introduction: Congenital myotonic dystrophy
(CDM) occurs when symptoms of myotonic dystrophy present
at birth. In this study we evaluated the relationship between
physical function, muscle mass, and age to provide an assessment of the disease and help prepare for therapeutic trials.
Methods: CDM participants performed timed functional tests
(TFTs), the first 2 minutes of 6-minute walk tests (2/6MWTs),
and myometry tests, and also performed dual-energy X-ray
absorption (DEXA) scans. Healthy controls (HCs) performed
TFTs, 6MWTs, and myometry. Results: Thirty-seven children
with CDM and 27 HCs (age range 3–13 years) participated in
the study. There were significant differences in the 10-meter
walk (11.3 seconds in CDM vs. 6.8 seconds in HC) and 2MWT
(91 meters in CDM vs. 193 meters in HCs). DEXA lean mass
of the right arm correlated with grip strength (r 5 0.91), and
lean mass of the right leg correlated with 6MWT (r 5 0.62).
Conclusion: Children with CDM have significant limitations in
strength and mobility. The tests performed were reliable, and
lean muscle mass may serve as a useful biomarker.
Muscle Nerve 000:000–000, 2016
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Myotonic dystrophy (DM1) is the result of a trinucleotide CTGn repeat expansion in the 30 untranslated region of the DMPK gene.1–4 This CTG
repeat can expand markedly between generations,
particularly when the mother is affected. Significant repeat expansions may lead to symptoms at
birth, known as congenital myotonic dystrophy
(CDM).5,6
Children with CDM have high mortality in the
newborn period and display significant impairments in physical function throughout childhood.7–16 Clinical features in children with CDM
include hypotonia, weakness, feeding difficulties,
cognitive impairment, and respiratory failure
requiring intubation and ventilation immediately
after birth.8,10,14,16–19
A cross-sectional study has identified hand
weakness and difficulty with ambulation as affecting quality of life in CDM.20,21 Despite this, few
data have been collected for functional outcome
measures in CDM.22,23 One study attempted to
measure isometric muscle strength using handheld
myometry in children with CDM.22 However, the
investigators were unable to collect sufficient data
due to the participants having difficulty following
directions.22 Another study measured timed functional tests, manual muscle tests, and pulmonary
function tests in 17 individuals with CDM > 10
years of age.24 Physical ability in children with
CDM had been measured previously using the
motor function measure (MFM)25 and a similar
motor function scale.22 However, the earlier studies were limited by sample size, age restriction, and
a smaller subset of functional measures.22,23
In this study we aimed to comprehensively evaluate available outcome measures for use in therapeutic trials. Accordingly, the study goals were to:
(1) compare timed functional tests for healthy controls (HCs) and children with CDM; (2) determine
the feasibility, reliability, and agreement of functional measures; and (3) identify any relationships
between dual-energy X-ray absorption (DEXA)
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lean mass and functional measures for children
with CDM.
METHODS

Participants with CDM between 3 and 13 years
of age were enrolled at the University of Utah
(n 5 34) and the University of Western Ontario,
Canada (n 5 3). The institutional review boards at
both institutions approved all study procedures,
and informed consent was obtained. Participants
were included if they met the research definition
for CDM and had no other major medical illnesses.20 CDM was defined as: (1) symptoms present at birth; (2) newborn symptoms, including
hypotonia, feeding difficulties, talipes equinovarus,
or respiratory failure; and (3) confirmed genetic
testing revealing a CTG repeat in the DMPK gene
with > 200 repeats. Subjects were excluded if they
had any non-DM1 illness that would interfere with
their ability to complete study procedures. HCs
(n 5 27) between 3 and 13 years of age were
included if they had no major medical problems
and were not currently on any medications.
Timed Functional Testing. Timed functional tests
(TFTs) were performed in accordance with previous pediatric studies of neuromuscular disorders.22,23,26–28 Timed activities included: time to
climb 4 stairs (4SC); time to rise from the floor
starting in a supine position; 10-meter (m) run;
and 10-m self-selected walking speed. A stopwatch
was used, and participants were given a maximum
of 60 seconds (s) to complete all tasks. If a subject
was unable to complete the task, the time was not
recorded. Correlations were analyzed for children
with CDM between TFTs and age, and also for
TFTs and number of CTGn repeats.
6-Minute and 2-Minute Walk Tests. The 6-minute
walk test (6MWT) was conducted in HCs and children with CDM along a 25-m course using criteria
cited in previous studies.26–28 The distance at 2
minutes (min) was recorded during the 6MWT
and was referred to as the 2-minute walk test
(2MWT). Orthotics and assistive devices for ambulation were allowed. Continuous verbal encouragement was given from the evaluators and parents
during the test to ensure the subjects remained
attentive. The 6MWT was performed over 2 consecutive days in children with CDM for reliability testing. HCs performed the walk test on a single day.
Subjects who were physically unable to walk were
given a distance of 0 m for the 6MWT and 2MWT.
Grip and Pinch Myometry. The average of 3 trials
of grip and pinch measurements for maximum voluntary isometric contraction (MVIC) was collected
from both hands in HCs and children with CDM.
Handgrip was collected using a digital hand
2
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dynamometer (Jamar Plus1; Sammons Preston,
Bolingbrook, Illinois). Jaw chuck pinch and lateral
pinch were collected using a digital pinch gauge
(Jamar Plus1). Participants were instructed to grip
and pinch as hard as they were able with the hand
and forearm resting at their sides in 908 of elbow
flexion and neutral pronation/supination.
Handheld Myometry. Strength testing was collected
in HCs and children with CDM (age range 4–13
years) on 4 muscle groups, bilateral shoulder
abductors and ankle dorsiflexors using a Commander Muscle Tester (PowerTrack II; JTECH
Medical, Midvale, Utah). A make test was conducted. Shoulder abduction was collected with the
patient in the seated position with the shoulder
abducted to 908 and the elbow flexed a few
degrees with a dynamometer placed proximal to
the lateral humeral epicondyles. Ankle dorsiflexion
was tested in the seated position with the legs
flexed over the edge of the table with shoes off,
lower leg stabilized above the ankle joint, and the
myometer placed on the dorsum of the foot over
the metatarsals. Dorsiflexion with inversion was
allowed, because many children with CDM had difficulty isolating pure dorsiflexion. Three trials were
collected per muscle, and the average was
recorded.
Dual-Energy
X-Ray
Absorptiometry. Whole-body
DEXA scans were performed on children with
CDM using a Hologic Discovery (Hologic, Inc.,
Marlborough, Massachusetts) machine running
Apex version 3.2 software. HCs did not undergo
DEXA scans. Children were positioned according
to manufacturer recommendations. On occasion,
when cooperation could not be solicited from a
few of the children, a cotton sheet was used to
swaddle the child to minimize movement artifact.
Scans of the lean mass of the right arm and leg
were acquired and analyzed by a licensed and certified technician from the International Society for
Clinical Densitometry.
Bruininks–Oseretsky Test of Motor Proficiency—2nd
Edition. The Bruininks–Oseretsky Test of Motor
Proficiency—2nd edition (BOT-2) fine motor control and manual coordination subtests were
attempted in 25 of the children with CDM
between 4 and 13 years of age. Each subject’s percentile rank was calculated in relation to previously established standardized and norm-referenced
values.29

Independent-sample t-tests or
Wilcoxon 2-sample tests were used to compare the
differences in functional measures between CDM
and the control group. Pearson correlation was
used to determine the relationship between the

Statistical Analysis.
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Table 1. Participant demographics
Variable
Number
Age (mean 6 SD), in years
Age range, in years
CTGn repeats ( 6 SD)
(n 5 30)
Range of CTGn repeats
(n 5 30)
Gender
Male [n (%)]
Female [n (%)]
Ethnicity
Hispanic [n (%)]
Not Hispanic [n (%)]
Race
Asian [n (%)]
White [n (%)]

CDM

Control

37
7.4 6 3.0
3–13.2
1,226.9
( 6 462.6)
400-2,530

27
9.7 6 2.3
5.6–13.9
Not tested

18 (49%)
19 (51%)

12 (44%)
15 (56%)

3 (8%)
34 (92%)

2 (7%)
25 (93%)

1 (3%)
36 (97%)

0
27 (100%)

Not tested

upper and lower extremity outcome measures and
the DEXA lean mass. Intraclass correlation (ICC)
and Bland–Altman analyses were used to test the
reliability between days 1 and 2 of the 6MWT and
2MWT. Family-wise error was corrected for by
using Holm–Bonferroni methods. All analyses were
conducted using SAS version 9.4 (SAS Institute,
Inc., Cary, North Carolina) statistical software, and
P < 0.05 was considered significant.
RESULTS
Participant Demographics. This study included 37
participants with CDM and 27 HCs. Detailed
demographic data, including age, gender,

ethnicity, race, and CTGn repeat number, are presented in Table 1.
When comparing TFTs,
children with CDM performed significantly lower
than HCs on all 4 measures (10-m walk, 10-m run,
time to rise from floor, 4SC), after adjusting for
age. Findings were as follows (mean 6 standard
deviation): 10-m walk: CDM (n 5 31) 11.3 6 6.9 s,
HCs (n 5 26) 6.8 6 1.8 s (P < 0.001); 10-m run:
CDM (n 5 29) 6.1 6 3.1 s, HCs (n 5 25) 3.2 6 0.5 s
(P < 0.001); time to rise from the floor: CDM
(n 5 26) 9.4 6 6.3 s, HCs (n 5 25) 2.0 6 0.6 s
(P < 0.001); and 4SC: CDM (n 5 29) 7.0 6 7.6 s,
HCs (n 5 26) 1.5 6 0.3 s (P < 0.001).
Some participants with CDM were unable to
complete the test for physical, behavioral, or cognitive reasons. Behavioral difficulties included participants with CDM being easily distracted,
uncooperative, or sometimes refusing to perform
the tests. A time was recorded only if the participant was able to complete the test. The percentages of participants with CDM who were scored
for the TFTs were: 10-m walk, 83.8%; 10-m run,
78.4%; 4SC, 78.4%; and time to rise from floor,
74%. Figure S1 (refer to Supplementary Material,
available online) provides an analysis of TFT
results versus age as a function of CTGn repeat
length (>100 or < 1,000) in children with CDM.
Timed Function Testing.

The total
6MWT distance has been previously reported.30
6-Minute

and

2-Minute

Walk

Tests.

FIGURE 1. Comparison of timed function tests for congenital myotonic dystrophy patients and healthy controls by age. Open circles,
solid line, HCs; crosses, dashed line, CDM.
Physical Function in CDM
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and thereby indicates our 6MWT had test–retest
reliability. Likewise, for the 2MWT, the mean difference between days 1 and 2 was 0.66 m/min or
1.32 m over 2 min. The 2MWT overall has a smaller
mean difference than 6MWT. No systematic
change was noted, as the Bland–Altman plot shows
random changes in the mean values between the 2
test occasions.
Correlation of Timed Functional Tests and Walk

The first 2 minutes of the 6MWT correlated
highly with the overall 6 MWT distance (Table 2).
Gait speed items, 10-m run and 4SC, and 10-m run
and 10-m walk had strong correlations. Modest correlations were found between all other comparisons
(Table 2).

Tests.

Handheld Myometry. Handheld myometry results
are reported in Supplementary table S1, available
online. The average age of children with CDM
able to complete shoulder abduction myometry
was 9.51 years and 9.98 years for ankle dorsiflexion
myometry.

DEXA lean
mass results by age and gender for children with
CDM (n 5 29) are shown in Supplementary figure
S2, available online. The mean DEXA total lean
mass for males (15,058 g/cm2) was higher than
that for females (13,013 g/cm2), but the difference
was not significant (P 5 0.539). The total lean mass
correlated significantly with age for children with
CDM (r 5 0.808, P < 0.001). DEXA lean mass of
the right arm correlated well with all 3 measures
of hand strength (Table 3). However, when comparing DEXA lean mass of the lower extremity and
total lean body mass with 10-m walk or 2MWT/
6MWT performances, only modest correlations
were found for each measure (2MWT, r 5 0.59;
6MWT, r 5 0.62; 10-m walk, r 5 –0.38; Tables 2
and 3).
Dual-Energy

FIGURE 2. Bland–Altman graphs of 2MWT and 6MWT test–
retest reliability.

Behavioral difficulties prevented some participants
(11%) from completing the full 6MWT, but all
participants were able to complete at least the first
2 minutes. Similar to the 6MWT, 2MWT results
were significantly different in the CDM population
(CDM
91 6 58.9 m
vs.
HC
193 6 22.7 m;
P < 0.0001), as shown in Figure 1. Both walk tests
had high test–retest reliability (2MWT ICC 5 0.94,
6MWT ICC 5 0.96). Bland–Altman plots of test–
retest reliability are presented in Figure 2. For the
6MWT, the mean difference between days 1 and 2
was close to 0, 1.46 m/min or 8.52 m over 6 min,

X-Ray

Absorptiometry.

Table 2. Pearson coefficients for walk tests and timed functional tests
Measure
DEXA total lean
mass
2MWT
6MWT
10-m walk
4-stair climb
Rise from floor
10-m run

4

DEXA total lean
mass

2MWT

6MWT

10-m walk

4-stair
climb

Rise from
floor

10-m run

1.00
0.62
(P 5 0.001)
0.62
(P 5 0.001)
20.39
(P 5 0.066)
20.44
(P 5 0.043)
20.28
(P 5 0.239)
20.54
(P 5 0.012)

Physical Function in CDM

1.00
0.98
(P < 0.0001)
20.72
(P < 0.0001)
20.56
(P 5 0.0016)
20.66
(P 5 0.0003)
20.71
(P < 0.0001)

1.00
20.76
(P < 0.0001)
20.60
(P 5 0.0012)
20.66
(P 5 0.0006)
20.78
(P < 0.0001)

1.00
0.73
(P < 0.0001)
0.57
(P 5 0.0025)
0.82
(P < 0.0001)

1.00
0.55
(P 5 0.0042)
0.85
(P < 0.0001)

1.00
0.67
(P 5 0.0003)

MUSCLE & NERVE
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Table 3. Pearson correlation for DEXA results compared with functional tests
Measure
Total body lean mass
Lean mass of right arm
Right grip
Right lateral pinch
Right jaw chuck

Measure
Total body lean mass
Lean mass of right leg
2MWT
6MWT
10-m walk*

Total body
lean mass

Lean mass
of right arm

Right grip

Right pinch

Right jaw
chuck

1.00
0.91 (P < 0.0001)
0.83 (P < 0.0001)
0.77 (P 5 0.0009)

1.00
0.94 (P < 0.0001)
0.86 (P < 0.0001)

1.00
0.78 (P < 0.0001)

1.00

1.00
0.84 (P < 0.001)
0.76 (P < 0.001)
0.73 (P < 0.001)
Total body
lean mass

Lean mass
of right leg

2MWT

6MWT

10-m walk

1.00
0.59 (P 5 0.0047)
0.62 (P 5 0.0034)
–0.38 (P 5 0.1345)

1.00
0.98 (P < 0.0001)
–0.73 (P < 0.0001)

1.00
–0.76 (P < 0.0001)

1.00

1.00
0.62 (P 5 0.001)
0.62 (P 5 0.001)
–0.39 (P 5 0.066)

*An inverse correlation is found between lean mass of the right leg and 10-m walk, as increasing lean mass should result in less time to complete the 10m walk.

Exploratory Measures. The BOT-2 assesses fine
motor control and manual dexterity. It was administered to 25 children with CDM between 4 and 13
years of age (average age 8.1 years). Ninety-four
percent of participants scored in the 0 to 2nd percentile when compared with norm-referenced values for fine motor control, manual coordination,
and fine motor composite. One subject scored in
the 8th percentile for fine manual control.
Seventy-two percent of children with CDM were
able to complete the fine manual control and
manual coordination subsets of the BOT-2.
DISCUSSION

In this study we have provided a cross-sectional
assessment of physical function in children with
CDM. There is evidence that strength improves
throughout childhood, albeit at different rates,
depending on the outcome measure used. However, despite improvement, the children with CDM
who were evaluated scored lower than their
healthy peers. In general, the improvement
between age groups on the measures assessed
stands in contrast to findings from adults with
DM1, where strength declined over time.31,32 It is
possible that CDM is a developmental disorder,
and that natural muscle maturation may partially
compensate for the underlying pathophysiology.
Future studies should attempt to compare individuals with adult-age CDM to adults with DM1 and,
likewise, children with CDM to individuals with
childhood-onset DM1.
This study was designed to prepare for clinical
trials in children with CDM by evaluating the feasibility, reliability, and validity of functional outcome
measures. Overall, the measures assessed met
Physical Function in CDM

criteria for inclusion in clinical trials in that they
were reliable and generally completed. The 6MWT
and 2MWT were found to have excellent test–
retest reliability. It appears that children with CDM
have decreased performance on TFTs if they possess >1,000 CTGn repeats when compared with
their peers with CDM who have <1,000 CTGn
repeats (see Supplementary Fig. S1). DEXA lean
body mass may be an effective clinical tool to utilize in future studies for predicting functional
upper extremity strength and may be a potential
biomarker to monitor functional changes in disease progression.
Given the association of intellectual impairment in children with CDM, functional outcomes
may have variable completion rates.9,21,24,33,34 The
TFTs and 6MWT described had acceptable rates of
completion. Future studies may consider using the
2MWT rather than the 6MWT, because more children were able to complete the first 2 minutes of
the 6MWT than the full 6MWT. Tests with the lowest completion rates for children with CDM included spirometry, BOT-2, and myometry of the ankle
dorsiflexors. We also found that children with
CDM displayed a floor effect on the BOT-2, whereby no subjects who were able to complete the
test scored above the 8th percentile on any of the
subtests of fine manual control and manual
coordination.
There are limitations to our study. First, the
study is cross-sectional in nature. Future longitudinal studies will be required to obtain withinparticipant comparisons. Second, many of our participants were remote from the study center and
required travel, which may have contributed to
fatigue. Third, intellectual impairment and
MUSCLE & NERVE
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behavioral problems in some children with CDM
limited the completion rate of some tests. Finally,
the first 2 minutes of the 6MWT were used rather
than a separate 2MWT. Future results may vary
with the use of the actual 2MWT as a stand-alone
measure.
Overall, this study has defined some of the limitations of physical function during childhood in
children with CDM. Due to the nature of CDM,
there was a degree of variability between each subject’s ability to complete the full battery of physical
function assessments. Children with CDM may display autism-like characteristics.9,21 Despite these
obstacles we found that most children with CDM
were able to complete the walk tests, TFTs, and
DEXA scans. Future studies should continue to
examine and seek to validate various measures of
functional mobility in children with CDM to better
understand disease progression and prepare for
clinical trials.
The authors thank Hillarie Slater (DEXA scan technician at the
University of Utah), Heather Hayes, PT, PhD, and Wei Chen, PhD
(both from the University of Utah), for their contributions to this
work.
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